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ABSTRACT
Once-daily fingolimod 0.5 mg (FTY720; Gilenya,
Novartis Pharma AG, Basel, Switzerland) is a
sphingosine 1-phosphate receptor modulator
that is approved for the treatment of relapsing
multiple sclerosis (MS); currently, this includes
approval in 13Latin American countries. However,
despite a well-characterized efficacy and safety
profile in a large clinical development program,
thus far there has been limited representation of
patients from across the Latin American region.
Differences in MS disease characteristics have been
reported for the Latin American population
compared with Caucasians, which may be
additional to recent improvements in MS
diagnosis. Furthermore, healthcare provision and
regional socioeconomic factors exist that are
unique to Latin America compared with other
regions. Therefore, to optimize MS treatment
pathways and improve patient clinical outcomes,
it is important to investigate the efficacy and safety
profile of fingolimod using ethnically relevant
data. Here, we review key data from Hispanic
patients enrolled in the fingolimod clinical trial
program, summarize recent findings from the
FIRST LATAM study, and appraise fingolimod
data from real-world patient populations.
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INTRODUCTION
Fingolimod (FTY720; Gilenya, Novartis
Pharma AG, Basel, Switzerland) is a first-in-
class, orally administered sphingosine-1
phosphate receptor (S1PR) modulator that is
approved for the treatment of relapsing forms of
multiple sclerosis (MS) [1]. It is currently
approved in more than 80 countries globally,
including the following 13 Latin American
countries: Argentina, Brazil, Chile, Colombia,
Costa Rica, Ecuador, El Salvador, Guatemala,
Mexico, Panama, Peru, Uruguay, and
Venezuela.
To date, more than 114,000 patients
worldwide have been treated with fingolimod
in clinical trial and post-marketing settings,
with a total patient exposure of approximately
195,000 patient-years [2]; indeed, the efficacy of
fingolimod has been well established. In
pivotal, phase 3, controlled clinical trials,
fingolimod demonstrated significant
reductions in annualized relapse rates (ARRs),
lesion-based magnetic resonance imaging (MRI)
activity, and brain volume loss (BVL) compared
with placebo and intramuscular (IM) interferon
beta-1a (IFNb-1a; Table 1) [3–5], with beneficial
effects sustained in long-term extension studies
[6–10]. The most recent assessments of ‘no
evidence of disease activity’ (NEDA), which
incorporates relapses, new/newly enlarged T2
MRI lesions, disability progression, and BVL to
form a four-component NEDA assessment of
disease activity, identified that the likelihood of
achieving NEDA-4 was more than fourfold
greater with fingolimod than with placebo at
2 years [11], and was more than twofold greater
with fingolimod than with IFNb-1a at 1 year
[12].
Furthermore, large real-world studies such as
PANGAEA and MSBase have shown that
patients with MS who switch from injectable
therapies to fingolimod are significantly less
likely to experience relapses or disability
progression [13–15], and also demonstrate
greater adherence to fingolimod than those
who switch to other injectables [16, 17].
Evidence also suggests that fingolimod is a
suitable therapy for patients switching from
natalizumab due to JCV seroconversion,
suboptimal response, or other tolerability
reasons [18, 19].
As with most MS treatments to date, clinical
trials of fingolimod have involved limited
representation of patients from across Latin
America. However, it is important to establish
the efficacy and safety profile of fingolimod
from ethnically relevant data to better inform
the optimization of MS treatment pathways and
thereby improve patient clinical outcomes,
particularly in light of the increased treatment
options for patients with relapsing–remitting
MS (RRMS) in the Latin American region.
This is pertinent because, as more
information on the prevalence and course of
MS disease in patients across Latin America has
become available, observations point to an
increase in the frequency of MS across the
region compared with a few decades ago [20].
The genetic characteristics of MS across Latin
America are unique due to marked
heterogeneous patient populations. A complex
ethnic picture may directly impact both the
genetic susceptibility to MS and the
interpretation of pharmacogenomics data
relating to MS drug therapies [21, 22]. This
may also be confounded by MS-related
environmental factors such as exposure to
sunlight and incidence of childhood infections
[23].
This review was conducted to summarize
key trial data regarding the use of fingolimod
for the treatment of MS across Latin America.
Searches were conducted in PubMed (January
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2015) using the terms fingolimod, Gilenya,
FTY720, multiple sclerosis, Latin America,
LATAM, South America, and Hispanic.
Searching of congress abstracts was also
conducted for the following meetings
between 2012 and 2014: American Academy
of Neurology (AAN), European Committee for
Treatment and Research in Multiple Sclerosis
(ECTRIMS), and Latin American Congress of
Multiple Sclerosis (LACTRIMS). Findings from
real-world patient populations and
information relating to the practical use of
fingolimod in clinics across Latin America
were also provided by co-authors. In
addition, we explore the recently published
analyses of data from Hispanic patients
enrolled in the fingolimod clinical trial
program [24]. We also further describe recent
findings from the FIRST LATAM study [25].
The analyses in this article are based on
previously conducted studies and do not
involve any new studies of human or animal
subjects performed by any of the authors.
FEATURES OF MS AND ITS
MANAGEMENT IN LATIN AMERICA
MS in Latin America
Worldwide, at least 2.3 million people have MS.
The epidemiology of MS features various
genetic and environmental factors, which
underlie global prevalence variations [26]. The
relative prevalence of MS in Latin American
countries has historically been considered low
when compared with North American and
European countries [27]. In recent years, MS
prevalence has increased in Latin America, as in
the rest of the world, with suggestions that this
is not just a result of improved diagnosis,
although the reasons are presently not fully
understood [20, 28]. Current estimates of
prevalence in the region range from 0.8 to
21.5 cases per 100,000 inhabitants, with an
incidence of 0.3–1.9 annual cases per 100,000
person-years [27].
In addition to increasing prevalence,
differences exist between MS disease
characteristics in Latin America and other
regions of the world, particularly with regard
to factors such as gender, age of onset, relative
proportions of patients with relapsing versus
progressive MS, and number of familial cases. A
systematic review of the epidemiologic profile
of MS in Argentina has suggested a less
pronounced female:male bias in MS prevalence
compared with other regions (1.5:1 vs. 2.6–3.2:1
in Sweden/Canada) [29–31]; however, these
estimates can be variable, with Brazilian
reports of the female:male MS prevalence of
4.1:1 [32]. A review of MS epidemiology in
Argentina also reported the proportions of
patients with relapsing–remitting (65.5%),
secondary progressive (21.5%), primary
progressive (10.6%), and progressive relapsing
MS (2.4%) [29]—although the reported rates of
RRMS in Latin America are again variable
(ranging from 50% in Ecuador [33] to 91% in
Brazil [32, 34]). Nevertheless, this differs from
findings in Europe, for instance where
relapsing/progressive proportions were
identified as 77.4%/22.6% [35]. It is plausible
that these differences are the result of
historically less-effective diagnosis, with fewer
people diagnosed and treated early in the
disease course in Latin America, leading to the
identification of more progressive forms than in
Europe. It is reasonable to speculate that this
could change over time, with improved
diagnosis and earlier initiation of more
effective MS treatments across Latin America
[36].
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The immune profile of Latin Americans may
also impact upon the course of MS. There is a
reported relationship between childhood solar
exposure and MS prevalence, possibly due to
the immunomodulatory effects of vitamin D
[36, 37]; although the risk is not the same for
everybody [38]. Furthermore, the immune
response may also be affected by
environmental factors such as parasitic
infections [39]. The ‘hygiene hypothesis’
proposes that MS is less common in the
developing world than in countries with lower
levels of childhood infection. In support of this,
a striking near-dichotomous relationship has
been demonstrated between the prevalence of
MS and that of Trichuris trichiura (a surrogate
marker for other parasitic infections and low
levels of community sanitation), with a low
prevalence of MS correlated with a high
prevalence of Trichuris infection [40].
Management of MS in Latin America
The advent of oral treatments for RRMS, such as
fingolimod and teriflunomide, has expanded
treatment options in Latin America. Availability
of these disease-modifying therapies provides
an opportunity for clinicians to improve
management and optimize the treatment of
patients with RRMS in clinical practice. Indeed,
recent guidelines have detailed
recommendations for treatment optimization
specifically for Latin America [36]. For example,
in accordance with local drug availability and
regulatory requirements, fingolimod has been
recommended as an option for treatment
initiation and for patients with a suboptimal
response [36].
In addition to clinical efficacy and safety
information for particular disease-modifying
therapies, in Latin America, there are also
regional socioeconomic issues with respect to
drug availability, access to healthcare, and
awareness of MS. For instance, in the context
of limited drug intellectual property protection
in some countries, there is the potential for
patients to obtain and switch from originator
licensed drugs to non-proprietary generic copies
[41]. The use of such generics can be associated
with unpredictable safety and efficacy
implications [42].
The potential difference in genetic
susceptibility and disease course may also
impact on responsiveness to therapeutic
agents in Latin Americans. This is seen in
other minority ethnic populations, with a
reduced response to IFNb-1a reported among
African Americans, for example, when
compared with the US white population [43].
Overall, it is therefore important that data
relating to the efficacy and safety/tolerability of
fingolimod in Latin America should be
generated by studies drawing from the
appropriate ethnic backgrounds. Given the
combination of epidemiologic and
socioeconomic factors unique to Latin America
versus other regions, data from defined ethnic
groups will help clinicians to refine the
selection of the best possible treatment
options for patients with RRMS.
EXPERIENCE WITH FINGOLIMOD
IN LATIN AMERICA
Availability of fingolimod has increased across
Latin America in recent years; it is now
approved in 13 countries in the region. As a
result, experience with fingolimod in Latin
America is broadening, with a range of studies
reporting efficacy and safety outcomes, some of
which are summarized in Table 2.
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Phase 3 Clinical Study Efficacy and Safety
Data for Fingolimod in the Hispanic
Population
A post hoc analysis focused on the Hispanic
cohort from the three pivotal, phase 3 studies of
fingolimod (key results from which are
summarized in Table 1) [3–5, 24]. Pooled
efficacy and safety data from all randomized
Hispanic patients (n = 181) gave the largest
possible dataset, with the following treatment
groups: fingolimod 0.5 mg (n = 89), IFNb-1a IM
(n = 65), and placebo (n = 27). Over the analysis
period, the ARRs in Hispanic patients were
numerically lower in the fingolimod 0.5 mg
group, with relative numerical reductions of
52% versus placebo and 35% versus IFNb-1a IM:
ARRs of 0.22 [95% confidence interval (CI)
0.14–0.35] for fingolimod, 0.46 (95% CI
0.24–0.88) for placebo, and 0.34 (95% CI
0.18–0.63) for IFNb-1a IM.
Importantly, relative reductions in ARR were
of similar magnitude in the Hispanic cohort and
in the overall population, indicating that
fingolimod has efficacy in this ethnic group
that is similar to that in the wider study
population.
First-dose administration of fingolimod is
associated with a transient decrease in heart rate
(HR) and slowing of atrioventricular (AV)
conduction, owing to well-understood and
expected pharmacodynamic effects of fingolimod
treatment initiation [44–46]. In the FREEDOMS
(ClinicalTrials.gov number, NCT00289978),
FREEDOMS II (ClinicalTrials.gov number,
NCT00355134), and TRANSFORMS
(ClinicalTrials.gov number, NCT00340834)
studies, the first-dose effects of fingolimod on HR
and rhythm typically resolved spontaneously
within 24 h [3–5, 45]. Symptoms of conduction
delays were reported in less than 1% of patients,
and were typically mild or moderate in severity.
The post hoc analysis of the Hispanic cohort
of the pooled population from these trials
reported data on first-dose observations that
were consistent with the overall population
[24]. A transient decrease in HR was observed
in some Hispanic patients, consistent with
findings in the overall population. In both the
overall population and in the Hispanic cohort,
HR started to attenuate 6 h after initial
fingolimod administration. No cases of
symptomatic bradycardia were reported in the
Hispanic patients. Newly occurring
electrocardiographic (ECG) events were
observed in 11.4% of the Hispanic patient
population receiving fingolimod, compared
with 9.4% of the IFNb-1a IM group and 3.8%
of the placebo group. These events included
first-degree AV block (occurring in 4.5% of
patients receiving fingolimod), which were
typically asymptomatic. In previous studies,
the rates of AV block in the overall population
of patients receiving fingolimod have been in
the range 0–5% [9–11, 15], which is consistent
with that observed in the Hispanic cohort.
Importantly, the majority (88.8%) of Hispanic
patients in the fingolimod group were
discharged at 6 h following the first dose.
The post hoc analysis of Hispanic patients
also reported on general adverse event (AE)
data. The overall incidence of AEs was similar
across the fingolimod, placebo, and IFNb-1a IM
groups. Nasopharyngitis, headache, and urinary
tract infection were among the most common
AEs in all three treatment groups [24].
Phase 4 Safety and Tolerability Findings
from the Open-Label FIRST LATAM Study
Whereas assessment of AEs in the phase 3
studies indicated that the safety profile of
fingolimod in Hispanic patients was consistent
with that reported in the overall patient
618 Adv Ther (2015) 32:612–625
population, the open-label FIRST LATAM
(ClinicalTrials.gov number, NCT01497262)
study was specifically designed to evaluate the
safety and tolerability of fingolimod in an
ethnically relevant MS patient population in
Latin American countries [25, 47]. FIRST
LATAM was a 16-week, multinational safety
study enrolling patients across eight countries,
including six from Latin America (Argentina,
Brazil, Colombia, Mexico, Panama, Peru), and
which had a study population including
patients with controlled diabetes mellitus and
certain cardiac and pulmonary conditions that
were excluded from pivotal studies [25].
In the FIRST LATAM study, first-dose
monitoring observations were systematically
collected in line with the study protocol and,
reassuringly, these were consistent with those
described in previous fingolimod clinical studies
[45]. Transient decreases in HR and blood
pressure started to recover by 6 h following the
first dose. Most (90.6%) patients were
asymptomatic during first-dose monitoring
and were discharged at 6 h post-dose.
Bradycardia and dizziness occurred in 3.6%
and 0.7% of patients, respectively. For all
patients, these symptoms resolved on the
same day without medical treatment and did
not require extended monitoring. Of the 130
(94.2%) patients who completed the study,
59.4% reported an AE and 5.1% reported a
serious AE (SAE). Events of particular interest
were bradyarrhythmias (8.7%), infections
(23.9%), hypertension (2.2%), and liver-related
investigations (3.6%).
Real-World Experience of Fingolimod
Across the Globe and in Latin America
Results from clinical trials cannot be generalized
to an entire disease population because of
restrictions in trial design such as patient
eligibility criteria and the type of patients
willing to enter a study. Hence, post-
marketing studies are important in providing
information about the use of a drug in a real-
world setting, which includes patient
populations that are not eligible for entry into
a clinical trial. Studies of real-life experience in
different populations support the short safety
and tolerability of fingolimod in clinical
practice [48–50]. First-dose observation data
from these studies are in line with the phase 3
trials data [48–50]. Fingolimod discontinuation
owing to AEs was higher at 3 months in clinical
practice (8.2%) than observed in clinical trials
(7.6%) [49]. However, it should be noted that
discontinuation owing to AEs was similar to
expected AEs and headache was the most
frequent cause of discontinuation (1.3%) [49],
reflecting the incidence of headache AEs in
pivotal clinical trials (26.5%) [51]. Overall, a low
incidence of specific AEs and SAEs was observed
in these real-world studies performed in
different patient populations [48–50], which
were consistent with the previously described
safety profile of fingolimod in phase 3 clinical
trials [3–5]. Furthermore, data collected from
these real-world studies are of interest because
some included patients who would have been
excluded from fingolimod pivotal studies owing
to systemic diseases, including diabetes
mellitus, cardiac and pulmonary diseases.
Fingolimod was well tolerated in patients with
these comorbidities [49, 52]. Nevertheless, the
long-term safety in these patients is still
unknown and needs further evaluation.
As real-world experience of fingolimod
treatment in Latin Americans accumulates, it
is becoming increasingly apparent that safety
outcomes are similar to those in populations
from the rest of the world. A summary of the
key findings from real-world studies of MS in
Latin America is given here.
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In a review of cardiovascular data from 180
patients with MS receiving a first dose of
fingolimod in Brazil [53], a total of 12 (6.7%)
patients required extended monitoring beyond
6 h owing to symptomatic bradycardia, whereas
in clinical trials symptomatic bradycardia was
reported by 0.6% of patients. This difference
may be due to less stringent exclusion criteria in
the clinical trials compared with the real-world
setting. Additionally, it should be noted that
many of the patients with ECG abnormalities
after fingolimod administration had existing
cardiac abnormalities at baseline. Reassuringly,
these patients did not develop complications
after fingolimod administration. As a
precautionary measure, three (1.7%) patients
were managed for right branch/second-degree
AV block (although a precise description of
these ECG abnormalities and outcomes was not
provided). Overall, at the time of publication,
179 (99.4%) patients in the study were
continuing fingolimod treatment.
Real-world experience of fingolimod
supports the clinical trial findings in
Hispanic patients that the effect of first-dose
administration on HR is typically
asymptomatic [24]. In a retrospective,
observational study of 78 patients in Chile,
first-dose observations during the initial 6 h
post-dose showed that no patient had
symptomatic bradycardia or required
hospitalization, with all patients meeting
discharge criteria [54]. Furthermore, the same
Chilean MS center reported that fingolimod
treatment in 88 patients (of whom 66% had
failed previous therapy) significantly reduced
ARR from 1.35 to 0.42 (P\0.0001) [55]. In
Argentina, an interim analysis of 92 patients
from the 2-year, open-label, prospective REAL
(Argentinean registry of patients treated with
fingolimod) study, which aims to include 200
patients, showed an effect of fingolimod on
HR during treatment initiation which was
similar to that reported in the FIRST LATAM
and pivotal studies. Of the 92 patients, three
(3.3%) required ECG monitoring beyond 6 h,
although all were discharged after 9 h of
observation; no patient had symptomatic
bradycardia [56]. The Argentinian, open-label,
prospective, multicenter ENCOMS [Experiencia
con el Tratamiento, Carga de la Enfermedad y
Necesidades Insatisfechas en Esclerosis
Mu´ltiple (Treatment Experience, Burden and
Unmet Needs in Multiple Sclerosis)] study of
266 patients demonstrated that MS relapses
can have a detrimental effect on patient
quality of life (QoL) [57]; the REAL study
showed benefits of fingolimod treatment on
QoL outcomes and treatment persistence [58].
In Puerto Rico, a single-center study of 50
patients suggested that, in the Hispanic
population, fingolimod can reduce the
development of MRI T1 hypointense lesions
(black holes) and brain atrophy after 1 year
[59]. In Mexico, an observational,
ambispective, multicenter study of 127
patients showed that fingolimod had a
greater beneficial effect on MS progression at
earlier compared with later stages of disease




Overall, this review indicates that the efficacy
and safety data for fingolimod derived from
clinical and real-world evaluations of Hispanic
and Latin American patients are very similar to
those reported for the overall study populations
and patients from other countries, including
observations during first-dose monitoring [3–5,
52]. These findings provide reassurance for
clinicians and patients alike. However, studies
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of efficacy in Latin American patients thus far
have generally been limited to the evaluation of
relapse rate outcomes. In the clinical trial
program, fingolimod further demonstrated a
consistent significant reduction in
inflammatory disease activity and BVL, as
measured by MRI, and significant effects on
several measures of disability in the overall
study populations [3–5]. Additional research
would ideally investigate these treatment
responses specifically in patients with MS from
Latin America [36].
It is also important to acknowledge
particular health issues endemic in Latin
America, such as the high prevalence of
tuberculosis, influenza, herpes zoster, and
human T-lymphotropic virus infection [61].
This is an important consideration because,
while the overall incidence of infections was
similar between fingolimod and control groups
in the phase 3 studies, pooled analyses showed a
slightly higher incidence of infections such as
herpes zoster in patients treated with
fingolimod (1.5%) than in those receiving
placebo (0.8%) [51]. This trend appears
consistent with findings in Latin American
patients. As patient exposure to fingolimod
increases in the region, ongoing vigilance for
opportunistic infections is certainly warranted
but, so far, no new safety signals have emerged.
A recent, randomized, placebo-controlled study
in patients with MS looked at immune response
to influenza and tetanus vaccines; the results
indicated that while patients receiving
fingolimod were able to mount immune
responses, their response rates to the vaccines
were reduced when compared with those
receiving placebo [62]. Thus, label
recommendations and existing risk
management plans should be carefully
adhered to [1]. Current label recommendations
state that, as with any immune-modulating
drug, patients should be monitored for signs
and symptoms of infection during fingolimod
treatment and for 2 months after
discontinuation, and treatment should not be
initiated in patients with active acute or chronic
Table 3 Availability of therapy options for multiple

















Patient-family associations 20 (100)
MS centers/clinics 12 (60)
National clinical studies 11 (55)
International clinical studies 12 (60)
MS academic associations 10 (50)
Clinical trials 10 (50)
Treatment guides 10 (50)
Therapeutic effectiveness trials 2 (10)
North America Mexico, Cuba, Puerto Rico, Dominican
Republic; Central America Costa Rica, El Salvador,
Guatemala, Honduras, Nicaragua, Panama; South
America Argentina, Bolivia, Brazil, Colombia, Chile,
Ecuador, Paraguay, Peru, Uruguay, Venezuela
MS multiple sclerosis
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infections [1]. With regard to herpes zoster
infection, patients without a history of
chickenpox or without vaccination against
varicella zoster virus (VZV) should be tested
for antibodies to VZV, and vaccination of
antibody-negative patients should be
considered prior to commencing treatment [1].
Aside from efficacy and safety
considerations, it is also worth considering
that algorithms for the management of MS in
Europe/North America may not reflect practical
issues relating to healthcare provision in Latin
America [61]. While fingolimod is now
approved in 13 Latin American countries,
some data suggest that it is not yet fully
available. For example, an unofficial survey
conducted at meetings in Colombia and
Ecuador in 2011 found that fingolimod was
available in only four of the 20 countries
included in the analysis, compared with all 20
countries having access to IFNb (Table 3) [63].
However, it is reasonable to assume that there
have been improvements in fingolimod
availability in Latin America since 2011, with
further improvements expected over the next
few years. As fingolimod becomes more widely
available and easier to prescribe, the increased
experience of this compound across Latin
America will become ever more relevant and
allow better assessment of the fingolimod
risk:benefit ratio in this ethnic group.
CONCLUSIONS
Expanding clinical and real-world experience of
fingolimod in patients from Latin America
indicates that efficacy and safety outcomes are
similar to those of patients from the rest of the
world. It is important to consider the particular
features of MS in Latin America, as well as
socioeconomic factors, when tailoring
treatment optimization strategies for patients
across the region, and further research is
required in this ethnic group. However,
overall, current data show that fingolimod
should be considered a good option for
treating Latin American patients with MS early
in the course of the disease.
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